Share-based Payment Arrangement, Expense of VERTEX PHARMACEUTICALS INC / MA from 31 Mar 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
VERTEX PHARMACEUTICALS INC / MA quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2010 to 30 Sep 2025.
  • VERTEX PHARMACEUTICALS INC / MA Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $194,900,000, a 5.6% increase year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $696,100,000, a 5.8% decline year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA annual Share-based Payment Arrangement, Expense for 2024 was $698,500,000, a 20% increase from 2023.
  • VERTEX PHARMACEUTICALS INC / MA annual Share-based Payment Arrangement, Expense for 2023 was $581,200,000, a 18% increase from 2022.
  • VERTEX PHARMACEUTICALS INC / MA annual Share-based Payment Arrangement, Expense for 2022 was $491,300,000, a 11% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

VERTEX PHARMACEUTICALS INC / MA Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $696,100,000 $194,900,000 +$10,300,000 +5.6% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $685,800,000 $167,300,000 +$13,100,000 +8.5% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $672,700,000 $166,100,000 -$25,800,000 -13% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $698,500,000 $167,800,000 -$40,800,000 -20% 01 Oct 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
Q3 2024 $739,300,000 $184,600,000 +$53,700,000 +41% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $685,600,000 $154,200,000 +$34,900,000 +29% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $650,700,000 $191,900,000 +$69,500,000 +57% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $581,200,000 $208,600,000 +$97,100,000 +87% 01 Oct 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $484,100,000 $130,900,000 -$4,700,000 -3.5% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $488,800,000 $119,300,000 +$5,400,000 +4.7% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2024 2024 Q2
Q1 2023 $483,400,000 $122,400,000 -$7,900,000 -6.1% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $491,300,000 $111,500,000 -$7,100,000 -6% 01 Oct 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
Q3 2022 $498,400,000 $135,600,000 +$32,600,000 +32% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $465,800,000 $113,900,000 +$9,300,000 +8.9% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $456,500,000 $130,300,000 +$15,100,000 +13% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q1
Q4 2021 $441,400,000 $118,600,000 +$21,534,000 +22% 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 $419,866,000 $103,000,000 +$3,461,000 +3.5% 01 Jul 2021 30 Sep 2021 10-Q 28 Oct 2022 2022 Q3
Q2 2021 $416,405,000 $104,600,000 -$12,589,000 -11% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2022 Q2
Q1 2021 $428,994,000 $115,200,000 -$506,000 -0.44% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $429,500,000 $97,066,000 +$5,464,000 +6% 01 Oct 2020 31 Dec 2020 10-K 10 Feb 2023 2022 FY
Q3 2020 $424,036,000 $99,539,000 +$14,119,000 +17% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $409,917,000 $117,189,000 +$27,502,000 +31% 01 Apr 2020 30 Jun 2020 10-Q 30 Jul 2021 2021 Q2
Q1 2020 $382,415,000 $115,706,000 +$21,915,000 +23% 01 Jan 2020 31 Mar 2020 10-Q 30 Apr 2021 2021 Q1
Q4 2019 $360,500,000 $91,602,000 +$12,659,000 +16% 01 Oct 2019 31 Dec 2019 10-K 09 Feb 2022 2021 FY
Q3 2019 $347,841,000 $85,420,000 -$112,000 -0.13% 01 Jul 2019 30 Sep 2019 10-Q 30 Oct 2020 2020 Q3
Q2 2019 $347,953,000 $89,687,000 +$7,251,000 +8.8% 01 Apr 2019 30 Jun 2019 10-Q 31 Jul 2020 2020 Q2
Q1 2019 $340,702,000 $93,791,000 +$15,655,000 +20% 01 Jan 2019 31 Mar 2019 10-Q 01 May 2020 2020 Q1
Q4 2018 $325,047,000 $78,943,000 +$2,697,000 +3.5% 01 Oct 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
Q3 2018 $322,350,000 $85,532,000 +$11,076,000 +15% 01 Jul 2018 30 Sep 2018 10-Q 31 Oct 2019 2019 Q3
Q2 2018 $311,274,000 $82,436,000 +$9,341,000 +13% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $301,933,000 $78,136,000 +$8,697,000 +13% 01 Jan 2018 31 Mar 2018 10-Q 01 May 2019 2019 Q1
Q4 2017 $293,236,000 $76,246,000 +$14,246,000 +23% 01 Oct 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
Q3 2017 $278,990,000 $74,456,000 +$13,247,000 +22% 01 Jul 2017 30 Sep 2017 10-Q 25 Oct 2018 2018 Q3
Q2 2017 $265,743,000 $73,095,000 +$11,153,000 +18% 01 Apr 2017 30 Jun 2017 10-Q 26 Jul 2018 2018 Q2
Q1 2017 $254,590,000 $69,439,000 +$13,967,000 +25% 01 Jan 2017 31 Mar 2017 10-Q 27 Apr 2018 2018 Q1
Q4 2016 $240,623,000 $62,000,000 +$17,354,000 +39% 01 Oct 2016 31 Dec 2016 10-K 13 Feb 2019 2018 FY
Q3 2016 $223,269,000 $61,209,000 -$4,525,000 -6.9% 01 Jul 2016 30 Sep 2016 10-Q 30 Oct 2017 2017 Q3
Q2 2016 $227,794,000 $61,942,000 -$1,319,000 -2.1% 01 Apr 2016 30 Jun 2016 10-Q 28 Jul 2017 2017 Q2
Q1 2016 $229,113,000 $55,472,000 -$1,912,000 -3.3% 01 Jan 2016 31 Mar 2016 10-Q 28 Apr 2017 2017 Q1
Q4 2015 $231,025,000 $44,646,000 +$2,264,000 +5.3% 01 Oct 2015 31 Dec 2015 10-K 15 Feb 2018 2017 FY
Q3 2015 $228,761,000 $65,734,000 +$19,598,000 +42% 01 Jul 2015 30 Sep 2015 10-Q 31 Oct 2016 2016 Q3
Q2 2015 $209,163,000 $63,261,000 +$20,817,000 +49% 01 Apr 2015 30 Jun 2015 10-Q 01 Aug 2016 2016 Q2
Q1 2015 $188,346,000 $57,384,000 +$10,804,000 +23% 01 Jan 2015 31 Mar 2015 10-Q 03 May 2016 2016 Q1
Q4 2014 $177,542,000 $42,382,000 01 Oct 2014 31 Dec 2014 10-K 23 Feb 2017 2016 FY
Q3 2014 $46,136,000 01 Jul 2014 30 Sep 2014 10-Q 30 Oct 2015 2015 Q3
Q2 2014 $42,444,000 01 Apr 2014 30 Jun 2014 10-Q 04 Aug 2015 2015 Q2
Q1 2014 $46,580,000 01 Jan 2014 31 Mar 2014 10-Q 04 May 2015 2015 Q1
Q4 2012 $113,804,000 $27,155,000 -$1,899,000 -6.5% 01 Oct 2012 31 Dec 2012 10-K 13 Feb 2015 2014 FY
Q3 2012 $115,703,000 $27,582,000 -$1,832,000 -6.2% 01 Jul 2012 30 Sep 2012 10-Q 06 Nov 2012 2012 Q3
Q2 2012 $117,535,000 $31,379,000 -$500,000 -1.6% 01 Apr 2012 30 Jun 2012 10-Q 08 Aug 2012 2012 Q2
Q1 2012 $118,035,000 $27,688,000 -$191,000 -0.68% 01 Jan 2012 31 Mar 2012 10-Q 10 May 2012 2012 Q1
Q4 2011 $118,226,000 $29,054,000 +$5,480,000 +23% 01 Oct 2011 31 Dec 2011 10-K 11 Feb 2014 2013 FY
Q3 2011 $112,746,000 $29,414,000 +$5,646,000 +24% 01 Jul 2011 30 Sep 2011 10-Q 06 Nov 2012 2012 Q3
Q2 2011 $107,100,000 $31,879,000 +$7,430,000 +30% 01 Apr 2011 30 Jun 2011 10-Q 08 Aug 2012 2012 Q2
Q1 2011 $99,670,000 $27,879,000 +$8,546,000 +44% 01 Jan 2011 31 Mar 2011 10-Q 10 May 2012 2012 Q1
Q4 2010 $91,124,000 $23,574,000 01 Oct 2010 31 Dec 2010 10-K 01 Mar 2013 2012 FY
Q3 2010 $23,768,000 01 Jul 2010 30 Sep 2010 10-Q 03 Nov 2011 2011 Q3
Q2 2010 $24,449,000 01 Apr 2010 30 Jun 2010 10-Q 09 Aug 2011 2011 Q2
Q1 2010 $19,333,000 01 Jan 2010 31 Mar 2010 10-Q 06 May 2011 2011 Q1

VERTEX PHARMACEUTICALS INC / MA Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $698,500,000 +$117,300,000 +20% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
2023 $581,200,000 +$89,900,000 +18% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
2022 $491,300,000 +$49,900,000 +11% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $441,400,000 +$11,900,000 +2.8% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $429,500,000 +$69,000,000 +19% 01 Jan 2020 31 Dec 2020 10-K 10 Feb 2023 2022 FY
2019 $360,500,000 +$35,453,000 +11% 01 Jan 2019 31 Dec 2019 10-K 09 Feb 2022 2021 FY
2018 $325,047,000 +$31,811,000 +11% 01 Jan 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
2017 $293,236,000 +$52,613,000 +22% 01 Jan 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
2016 $240,623,000 +$9,598,000 +4.2% 01 Jan 2016 31 Dec 2016 10-K 13 Feb 2019 2018 FY
2015 $231,025,000 +$53,483,000 +30% 01 Jan 2015 31 Dec 2015 10-K 15 Feb 2018 2017 FY
2014 $177,542,000 +$50,707,000 +40% 01 Jan 2014 31 Dec 2014 10-K 23 Feb 2017 2016 FY
2013 $126,835,000 +$13,031,000 +11% 01 Jan 2013 31 Dec 2013 10-K 16 Feb 2016 2015 FY
2012 $113,804,000 -$4,422,000 -3.7% 01 Jan 2012 31 Dec 2012 10-K 13 Feb 2015 2014 FY
2011 $118,226,000 +$27,102,000 +30% 01 Jan 2011 31 Dec 2011 10-K 11 Feb 2014 2013 FY
2010 $91,124,000 01 Jan 2010 31 Dec 2010 10-K 01 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.